What’s next in the Raskind/Peskind Prazosin research? They are directing the ADCS’ Peace AD trial which will test Prazosin, as a treatment for disruptive agitation, in people with moderate to severe Alzheimer’s disease. The trial is launching this spring in over 20 memory and long term care communities in the US.
The AlzForum’s editorial team provides a comprehensive recap of the last year in Alzheimer’s research and related public policy developments.
The updated guidelines reflect increased MCI research, the significance of MCI in clinical practice, and therapeutics in trials.